<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454259</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2006/08</org_study_id>
    <nct_id>NCT00454259</nct_id>
  </id_info>
  <brief_title>Fentanyl Ultra Low Doses Effects on the Nociceptive Threshold</brief_title>
  <acronym>FENTANULD</acronym>
  <official_title>Fentanyl Ultra Low Doses Effects on Human Volunteer's Nociceptive Threshold. Towards a Simple Pharmacological Test Able to Predict Pain Vulnerability, Post Operative Hyperalgesia Development Risk?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exaggerated pain and hyperalgesia are major issues after surgery and can lead to chronic
      pain. Opioid are parts of pain sensitization processes but remain absolutely necessary in the
      intraoperative period. NMDA receptor antagonists succeed in reducing this pain sensitization
      process. Recent studies show that in pain and opioid-experienced rats (POER) fentanyl ultra
      low doses do not induce analgesia, as observed in naive rats, but hyperalgesia. This is the
      first demonstration that a drug can induce opposite effect depending on individual history.
      We also observed a strong correlation between this hyperalgesic response in POER and the
      intensity of hyperalgesia they develop later, after inflammatory or surgical pain. The main
      aim of this study is to measure the dose effect response to fentanyl &quot;ultra low doses&quot; on
      human volunteer's nociceptive threshold, to determine if such an opposite response profile
      can be revealed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Principal Objective : &quot;Evaluate fentanyl &quot;ultra low doses&quot; effects on human volunteer's
           nociceptive threshold depending on their prior pain and opioid experience.&quot;

        -  Secondary Objective : &quot;Confirm the innocuousness of this test (the 3 &quot;ultra low doses&quot;
           used in this trial will be 10 to 1,000 fold lower than low doses use for anesthesia and
           analgesia) and to find the fentanyl ultra low dose that could be used to develop a pain
           sensitisation predictive test.&quot;

        -  Study design : Bicentric, prospective, randomized, double-blind study.

      Inclusion criteria :

      In both groups:

        -  18-40 years old male volunteer

        -  weight: 60 to 85 kg

        -  ASA score: 1

        -  Informed consent obtained from the patient

        -  Gender : Male

      In &quot;operated&quot; group:

      - At least one history of peripheral surgery under general anesthesia with opioid in the past
      five years

      Exclusion criteria :

      In both groups:

        -  The patient do not accept inclusion to the study

        -  Drug or alcohol abuse history

        -  Chronic use of analgesic drugs or history of chronic pain

        -  Analgesic or opioid consumption within the 12hs preceding the fentanyl or placebo
           injection

        -  Neurological and/or psychiatric disorder, inability to give informed consent

        -  Psychological trauma within the two year preceding the inclusion

        -  Any contraindication to fentanyl use

        -  Use of any medication interacting with fentanyl

        -  Exclusion period from the national healthy volunteer register

        -  Gender : Female

      In &quot;healthy&quot; group:

      - Any history of general anesthesia or surgery

        -  Study plan: comparing two groups that only defer by their surgical and opioid prior
           experience and will receive three fentanyl ultra low doses (10 to 1,000 fold lower than
           low doses use for anesthesia and analgesia) and placebo (cross over administration, one
           week wash out period).

        -  Number of subjects : 48
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nociceptive threshold evaluated with sternal electronical Von Frey mechanical stimulation. The stimulation will increase until the volunteer presses a trigger when the stimulation becomes painful.</measure>
    <time_frame>5 min after injection, and every 15 min during 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non invasive blood pressure (SBP, DBP), heart rate, respiratory rate, pulse oxymetry and cognitive functions evaluation (sedation score).</measure>
    <time_frame>all along the experimentation</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,5 µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,05 µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,005 µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0,9 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl/Placebo injection</intervention_name>
    <description>Ultra low dose intravenous injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In both groups:

          -  18-40 years old male volunteer

          -  Weight: 60 to 85 kg

          -  ASA score: 1

          -  Informed consent obtained from the patient

        In &quot;operated&quot; group:

          -  At least one history of peripheral surgery under general anesthesia with opioid in the
             past five years.

        Exclusion Criteria:

        In both groups:

          -  The patients do not accept inclusion to the study

          -  Drug or alcohol abuse history

          -  Chronic use of analgesic drugs or history of chronic pain

          -  Analgesic or opioid consumption within the 12hs preceding the fentanyl or placebo
             injection

          -  Neurological and/or psychiatric disorder, inability to give informed consent

          -  Psychological trauma within the two year preceding the inclusion

          -  Any contraindication to fentanyl use

          -  Use of any medication interacting with fentanyl

          -  Exclusion period from the national healthy volunteer register

        In &quot;healthy&quot; group:

          -  Any history of general anesthesia or surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe RICHEBE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gérard JANVIER, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude DUBRAY, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain ESCHALIER, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>jean DUALE CHRISTIAN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gisèle PICKERING, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux Département d'Anesthésie-Réanimation II</name>
      <address>
        <city>PESSAC Cedex</city>
        <state>Hôpital cardiologique</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hsu YW, Somma J, Hung YC, Tsai PS, Yang CH, Chen CC. Predicting postoperative pain by preoperative pressure pain assessment. Anesthesiology. 2005 Sep;103(3):613-8.</citation>
    <PMID>16129988</PMID>
  </reference>
  <reference>
    <citation>Kalkman CJ, Visser K, Moen J, Bonsel GJ, Grobbee DE, Moons KG. Preoperative prediction of severe postoperative pain. Pain. 2003 Oct;105(3):415-23.</citation>
    <PMID>14527702</PMID>
  </reference>
  <reference>
    <citation>Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000 Oct;93(4):1123-33. Review.</citation>
    <PMID>11020770</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </reference>
  <reference>
    <citation>Célèrier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001 Jun 1;21(11):4074-80.</citation>
    <PMID>11356895</PMID>
  </reference>
  <reference>
    <citation>Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993 Mar;52(3):259-85. Review.</citation>
    <PMID>7681556</PMID>
  </reference>
  <reference>
    <citation>Shen KF, Crain SM. Cholera toxin-B subunit blocks excitatory effects of opioids on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res. 1990 Oct 29;531(1-2):1-7.</citation>
    <PMID>1981160</PMID>
  </reference>
  <reference>
    <citation>Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci. 1998 Sep;19(9):358-65.</citation>
    <PMID>9786023</PMID>
  </reference>
  <reference>
    <citation>Richebé P, Rivat C, Laulin JP, Maurette P, Simonnet G. Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology. 2005 Feb;102(2):421-8.</citation>
    <PMID>15681961</PMID>
  </reference>
  <reference>
    <citation>Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000 Jun 9;288(5472):1765-9. Review.</citation>
    <PMID>10846153</PMID>
  </reference>
  <reference>
    <citation>Rivat C, Laulin JP, Corcuff JB, Célèrier E, Pain L, Simonnet G. Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-aspartate receptor antagonist ketamine. Anesthesiology. 2002 Feb;96(2):381-91.</citation>
    <PMID>11818772</PMID>
  </reference>
  <reference>
    <citation>Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport. 2003 Jan 20;14(1):1-7. Review.</citation>
    <PMID>12544821</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre LEROY / Clinical Research and Innovation Director</name_title>
    <organization>University Hospital, Bordeaux</organization>
  </responsible_party>
  <keyword>Postoperative Hyperalgesia</keyword>
  <keyword>Human volunteer</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Pain chronicisation</keyword>
  <keyword>Predictive test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

